Favorable rates of cardiovascular events with stringent cardiovascular monitoring and a lowered dose of ponatinib as second line treatment in chronic phase chronic myeloid leukemia (CML-CP) patients failing or intolerant to first-line second generation tyrosine kinase inhibitor (TKI) treatment: Results of the prospective PONS trial [0.03%]
严格的血管监测和降低剂量的 Ponatinib作为二线治疗方案对一线二代酪氨酸激酶抑制剂(TKI)治疗失败或不耐受的慢性期慢性粒细胞白血病(CML-CP)患者的血管事件有利：前瞻性PONS试验结果
Philipp le Coutre,Andreas Burchert,Susanne Saußele et al.
Philipp le Coutre et al.
Introduction: In chronic myeloid leukemia patients second-line treatment require careful consideration of response and tolerability. As most patients need a more efficient tyrosine kinase inhibitor, ponatinib at a lowered...
Dose reduced induction therapy (A)-AIDA in patients with AML, being unfit for standard 7+3 chemotherapy and Literature Review of AML treatment in unfit/older AML patients [0.03%]
剂量减低的诱导治疗(A)-AIDA方案在不能耐受标准IA方案的AML患者中的应用及老年或体质较差的AML患者的治疗概述文献回顾
Karin Mayer,Leonie Birk,Katjana Schwab et al.
Karin Mayer et al.
Introduction: The standard induction chemotherapy in newly diagnosed acute myeloid leukemia (AML) is 7 days cytarabine and 3 days daunorubicin. However older and frail patients cannot be treated intensively. Before hypome...
Emicizumab and acquired hemophilia A secondary to Multiple Myeloma [0.03%]
艾米西珠单抗与浆细胞瘤相关的获得性自身免疫性血友病A
Florence Cuschera,Marie-Christiane Vekemans,Cedric Hermans
Florence Cuschera
Acquired hemophilia A (AHA) is a severe condition characterized by significant bleeding and is sometimes associated with plasma cell disorders. Emicizumab, a bispecific antibody, mimics the coagulant function of factor VIII (FVIII) without ...
Case Reports
Acta haematologica. 2025 Apr 24:1-12. DOI:10.1159/000545442 2025
Concordance between tympanic and enteral temperature for early fever detection in hematologic intensive care unit patients: a prospective study [0.03%]
耳膜温度和食道温度对血液科重症监护病房发热患者早检测的对比研究
Florian Bouclet,Juliette Pénichoux,Sorina-Dana Mihailescu et al.
Florian Bouclet et al.
Introduction: Early detection of fever is crucial in neutropenic patients. Lack of precision in body temperature measurement can occur with peripheral site measurements. Furthermore, intermittent temperature monitoring ma...
Epiglottitis in Patients Treated for Acute Leukemia - Case Series and Systematic Review of the Literature [0.03%]
急性白血病患者中会厌炎的病例系列和文献系统回顾
Adi Sherban,Avraham Frisch,Alon Rozental et al.
Adi Sherban et al.
Acute epiglottitis is a medical emergency characterized by inflammation of supraglottic structures of the larynx and epiglottis. The clinical characteristics and course of this complication in acute leukemia (AL) is largely unknown. We pres...
Case Reports
Acta haematologica. 2025 Apr 17:1-21. DOI:10.1159/000545927 2025
Global, regional, and national burden of leukemia, 1990-2021: a systematic analysis for the global burden of disease study 2021 [0.03%]
2021年全球、区域和国家白血病疾病负担（1990~2021）：全球疾病负担研究系统分析结果
Xue Yao,Hui Wang,Linhua Yang
Xue Yao
Background: Leukemia is a group of diseases caused by malignant hematopoietic stem cell clones. Leukemia ranks 13th in incidence and 10th in mortality, according to the Global Cancer Statistics 2022. ...
STREAMLINE - Retrospective Cohort Study of FMS-like Tyrosine Kinase 3-Mutated Acute Myeloid Leukemia: Real-World Treatment Patterns and Clinical Outcomes of Patients in First Relapse or Refractory Diagnosis [0.03%]
STREAMLINE研究：FLT3突变急性髓系白血病患者一线治疗失败后的现实世界治疗模式和临床结局回顾性队列研究
Amer M Zeidan,Rebekah Yu,Yuexi Wang et al.
Amer M Zeidan et al.
Background Recent advances in genomic research have expanded the treatment landscape for acute myeloid leukemia (AML). This study examined treatment patterns and clinical outcomes among relapsed/refractory (R/R) FMS-like tyrosine kinase 3 (...
Tucidinostat combined with bortezomib, liposomal doxorubicin, and dexamethasone in multiple myeloma treatment [0.03%]
塔库欣联合硼替佐米、注射用伊立替康和地塞米松治疗多发性骨髓瘤
Jingyi Bi,Xuelin Dou,Ruqi Liang et al.
Jingyi Bi et al.
Background: We conducted a single-arm, open-label dose-exploration study to evaluate the safety and efficacy of the histone deacetylase inhibitor tucidinostat combined with bortezomib, liposomal doxorubicin, and dexametha...
Recombinant myeloid hematopoietic growth factors and clinical stimulation of acute myeloid leukemia cells: a narrative review [0.03%]
髓系造血生长因子重组体与急性髓细胞白血病的临床刺激：综述型叙述性文献回顾
Jason S Gilbert,Daniel A Pollyea,Thomas J Walsh et al.
Jason S Gilbert et al.
The advent of molecularly cloned hematopoietic growth factors (rhuG-CSF and rhuGM-CSF) enhanced the safety in treating acute myeloid leukemia (AML) by reducing the duration of neutropenia and thus decreasing the risks for infection. However...